We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




The Great Potential of Quantum Dot Imaging

By Biotechdaily staff writers
Posted on 10 Feb 2005
The development of nanocrystals known as quantum dots over the past 20 years has evolved into a new method that allows scientists to study cell processes at the level of an individual molecule, and may result in better ways to detect and treat cancers.

Semiconductor fluorescent quantum dots, called qdots, also have potential for high-resolution cellular imaging and the long-term study of single molecules and their movement within cells, according to researchers at the University of California, Los Angeles (UCLA; CA, USA) and Stanford University (Palo Alto, CA, USA). More...
The investigators published their work in the January 28, 2005, issue of the journal Science.

Qdot imaging is a new way to see biologic processes functioning within cells and in small animals. Probes can be attached to a specific protein or receptor to track it and see what other molecules it interacts with, what areas of the cell it is in, and what signaling pathways the protein may use for performing typical cell functions and abnormal functions that may result in cancer. Because qdots are nanocrystals--minuscule bits of rock one-billionth of a meter in size--they provide excellent contrast for imaging with an electron microscope.

The UCLA investigators believe that qdots might be utilized one day to do two things--diagnose and treat cancer. The technology will enable investigators to find a tumor within the body, look at it very specifically at the cellular level to determine what kind of cancer it is, and then maybe arm it with therapies developed to kill the disease.

Qdots have so much potential because they can be color-coded, with different colors utilized to label different cell mechanisms, different cancers, or different stages of the same cancer. At present, a positron emission tomography (PET) scan can tell clinicians the sites of tumors throughout the body, based on targeting the PET probe to an individual tumor marker. However, with qdots, several different markers of the same tumor could be simultaneously "painted,” producing a color barcode for real-time optical biopsy and diagnosis.

In the study, qdots were labeled with a positron-emitting isotope and injected into mice. Utilizing a PET scanner, scientists were able to watch over time as the qdots traveled through the vascular system and to the liver. The same technique may be used with patients, who could be injected with a mixture of different colored qdots that would label the cancer cells. Once they accumulate at the tumor site, the positrons emitted from the qdots could be imaged with PET scanners.






Related Links:
University of California, Los Angeles

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.